Amarin | AMRN - Operating Expenses


Amarin reported $51.48M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amarin USD 51.48M 113K Dec/2025
AstraZeneca USD 12.22B 4.04B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
DBV Technologies USD 47.9M 2.2M Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026